Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Arthritis Rheumatol. 2017 Aug 8;69(9):1722–1732. doi: 10.1002/art.40168

Table 1.

Agent Mechanism of Action Type of Clinical Trial
(number of subjects)
Trial Status
Rituximab CD20-directed ADCC Open-label, prospective (n = 30) Completed
XmAb5871 CD19-directed B cell inhibition Open-label, prospective (n = 21) Enrolling
Abatacept Co-stimulation blockade Case report (n = 1) -
Elotuzumab SLAMF7-directed ADCC Unstudied -
AMG-557 ICOS-directed Tfh inhibition Unstudied -